Alvaro Moreno-Ancillo

Alvaro Moreno-Ancillo

Auto-generated profile, based on publicly available information

Alvaro Moreno-Ancillo


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2026 in Journal of Asthma and Allergy
Verified
Journal Article
Open access
AMAna Montoro-Ferrer
Ana Montoro-Ferrer
MMMaria del Mar Moro Moro
Maria del Mar Moro Moro
FBFernando Parra Borreguero
Fernando Parra Borreguero
AMAlvaro Moreno-Ancillo
Alvaro Moreno-Ancillo
AOAlba Extremera Ortega
Alba Extremera Ortega
MGMaría Espinosa de Los Monteros Garde
María Espinosa de Los Monteros Garde
Dupilumab has demonstrated efficacy in type 2 severe asthma in clinical trials. Real-world data, particularly from Spain and including patients with prior biologic failure, remains limited. This study evaluated the effectiveness and safety of dupilumab in a Spanish cohort with type 2 severe asthma over 12 months. Retrospective, multicenter observational study in adult and adolescent patients (≥12 years) with type 2 severe asthma treated with dupilumab for at least six months. Clinical data, including exacerbations, lung function (FEV1), Asthma Control Test (ACT), quality of life (Mini-AQLQ), systemic corticosteroid use, and biomarkers (total IgE, eosinophil count, FeNO), were collected at baseline, 6, and 12 months. The EXACTO scale was used to assess response in non-oral corticosteroid (OCS)-dependent patients at 12 months. Subgroup analyses included chronic rhinosinusitis with nasal polyps (CRSwNP) and OCS-dependent patients at baseline. A total of 156 patients were included; 54.5% had received prior biologic therapies. Significant improvements (p<0.005) from baseline to 12 months were observed in exacerbations (1.43 to 0.20 per year), FEV1 (2530.10 to 2824.59 mL), ACT (15.84 to 21.31), and Mini-AQLQ (27.24 to 74.27). Total IgE and FeNO significantly decreased whereas blood eosinophilia increased. In non-OCS-dependent patients (n=78), 56.4% were good or super-responders according to the EXACTO scale. CRSwNP patients (n=66) significantly improved in asthma and nasal symptoms. Among OCS-dependent patients (n=35), 68.6% discontinued OCS by 6 months. Comparable clinical improvements in exacerbation rates, lung function and overall response were observed in biologic-naïve and biologic-pretreated patients, consistent with similar EXACTO scores (4.92 ± 1.29 vs. 4.55 ± 1.37, respectively; p=0.166). No new safety signals were identified. This Spanish real-world study confirms sustained effectiveness and acceptable safety of dupilumab in type 2 severe asthma, including patients with prior biologic failure and comorbid CRSwNP, supporting its use in routine clinical practice.

19 November 2026 in Clinical & Experimental Allergy
Verified
Journal Article
Closed access
PMPaula Méndez‐Brea
Paula Méndez‐Brea
EGEloína González‐Mancebo
Eloína González‐Mancebo
RCRoberto Bravo Cabañas
Roberto Bravo Cabañas
MCMoises A. Calderón
Moises A. Calderón
SDStephanie Dramburg
Stephanie Dramburg
PRPablo Rodríguez Del Río
Pablo Rodríguez Del Río